Módszerek összehasonlítása

	Adaptív Ökológiai Vizsgálat – Adaptív Populációszintű Megfigyeléses Tervezés	Adaptív vizsgálati terv
Tudományterület	Epidemiológia	Klinikai kutatás
Módszercsalád	Process / pipeline	Process / pipeline
Keletkezés éve	1990s–2000s (adaptive extensions of classical ecological designs)	1990s-2000s
Megalkotó	Building on classical ecological epidemiology (Durkheim, Snow, Morgenstern); adaptive extensions developed in late 20th–early 21st century methodological literature	Stephen Pocock, Christopher Jennison, and statistical methodologists; FDA formalized guidance 2019
Típus	Observational study design	Research Design
Alapmű	Morgenstern, H. (1998). Ecologic studies. In K. J. Rothman & S. Greenland (Eds.), Modern Epidemiology (2nd ed., pp. 459–480). Lippincott-Raven.	Pocock, S. J. (2005). Current issues in the design and interpretation of clinical trials. BMJ, 330(7500), 1118–1121.
Alternatív nevek	adaptive ecologic study, sequential ecological study, adaptive population-level design, adaptive group-level study	adaptive trial, adaptive design, response-adaptive randomization, RAR
Kapcsolódó	3	1
Összefoglaló	An adaptive ecological study is an observational epidemiological design in which the unit of analysis is a group or population (e.g., a region, country, or community) rather than an individual. It extends the classical ecological study by incorporating pre-specified interim decision rules that allow modifications — such as changes in geographic unit, time window, or exposure categorisation — as data accumulate, while preserving overall inferential validity. The design is used to explore population-level associations between aggregate exposures and aggregate outcomes.	An adaptive trial design allows pre-specified modifications to the trial based on interim data—such as sample size re-estimation, stopping for futility or efficacy, dropping ineffective arms, or shifting randomization ratios toward better-performing treatments. Developed systematically in the 1990s–2000s by statisticians like Pocock and Jennison, and formalized by the FDA in 2019, adaptive designs accelerate drug development, reduce exposure to ineffective treatments, and improve efficiency without inflating false-positive rates when properly executed.